Ingredion (INGR) Q4 2025 earnings review
Record Year Ends on a Sour Note
Ingredion posted record full-year results, but the Q4 exit velocity is concerning. While FY25 Adjusted EPS grew to $11.13, Q4 Adjusted Operating Income fell 8% YoY, missing the growth narrative. The culprit is a collapse in the U.S./Canada Food & Industrial Ingredients segment (-32% operating income) due to operational failures and weak demand. Management's FY26 guidance suggests a return to revenue growth (low-to-mid single digits), but the immediate outlook is grim: Q1 2026 operating income is guided to drop 'mid-double digits.' The thesis has shifted from momentum to recovery execution.
🐂 Bull Case
The strategic growth engine is working. T&HS volumes grew 4% in Q4, outpacing the broader business. Demand for clean label and sugar reduction remains a structural tailwind.
Ingredion returned $435M to shareholders in FY25 (including $224M in buybacks). With operating cash flow expected to remain robust ($820M-$940M in FY26), the floor for EPS is supported by a shrinking share count.
🐻 Bear Case
Food & Industrial Ingredients (US/Canada) operating income collapsed 32% in Q4. Management cites 'operational challenges' (Chicago plant) and weak sweetener demand. This is the company's cash cow, and it is currently hindering performance.
Guidance for Q1 2026 is alarming: sales down low-single digits and operating income down 'mid-double digits.' Lapping a strong 25Q1 explains some of it, but it indicates the operational fixes in the U.S. will not be immediate.
⚖️ Verdict: ⚪
Neutral. The long-term pivot to specialty ingredients (T&HS) is valid, but significant execution errors in the core US/Canada business and a weak Q1 outlook prevent a bullish rating. Wait for proof of operational stability.
Key Themes
US/Canada Profitability Collapse
The F&II US/Canada segment is in distress. Operating income plummeted 32% to $56M in Q4, driven by production challenges at a large facility (Chicago plant fire aftermath) and lower beverage volume. This segment's margin compressed dramatically to 12% from 16% a year ago.
T&HS Volume Recovery
Texture & Healthful Solutions (T&HS) proved its resilience with 4% volume growth in Q4. Clean label offerings are outpacing the segment average. However, despite the top-line win, operating income fell 4% due to one-time SG&A expenses, highlighting that volume hasn't fully translated to bottom-line leverage yet.
Cost Structure vs. Inflation
While the 'Cost 2 Compete' program is delivering, it wasn't enough to save the quarter. Q4 gross profit dropped in dollar terms vs Q3 ($430M vs $455M). The company expects corporate costs to be flat to up low-single digits in FY26, suggesting cost discipline remains a priority to protect margins.
South Korea Divestiture Drag
The sale of the South Korea business created a revenue hole, contributing to the 3% FY25 sales decline. While this is a strategic move to exit low-margin businesses, the immediate impact is a drag on reported growth metrics until fully lapped.
LATAM Stabilization
LatAm F&II showed signs of life, growing operating income 2% in Q4 despite volume headwinds. The segment regained momentum as market conditions improved, offering a counter-balance to the weakness in North America.
Other KPIs
Beat the FY24 result of $10.65 (+4.5% YoY). However, Q4 Adjusted EPS of $2.53 was down from $2.63 in the prior year, signaling decelerating earnings power entering 2026.
Down from $1.436B in FY24, reflecting a return to investment in working capital. Despite the drop, cash generation remains robust enough to fund the dividend and $224M in buybacks.
Down 2% reported and 4% excluding FX. The decline was driven by lower corn costs passed through to customers and the South Korea divestiture. The company has struggled to show organic top-line growth in dollar terms for several quarters.
Guidance
Stable/Slight Growth. The midpoint ($11.40) implies +2.4% growth over FY25's $11.13. This is a deceleration from the +4.5% growth seen in FY25, reflecting operational headwinds and a normalization of tax rates.
Accelerating. Improving from the -3% decline in FY25. Management expects greater volume demand to finally offset price mix headwinds.
Decelerating sharply. Management cites a 'challenging comparison' against a robust Q1 25 (+26% growth). This implies a very weak start to the year, likely in the range of -15% YoY.
Decelerating. Compared to +16% growth in FY25. While volume is growing, the pricing/mix dynamic appears to be limiting profit leverage.
Key Questions
Fixing US/Canada Operations
Operating income in US/Canada fell 32% this quarter. Specifically, what remaining hurdles exist at the Chicago/Argo facility, and when do you expect margins in this segment to return to the 16% range seen in 24Q4?
T&HS Profit Convertibility
Texture & Healthful Solutions grew volume 4% but operating income fell 4% in Q4. What specific 'one-time SG&A expenses' caused this, and why should investors be confident this segment will expand margins in FY26?
Q1 2026 Visibility
Guidance calls for Q1 operating income to be down mid-double digits. Beyond the tough comparison, does this forecast assume continued operational drags in the US, or is there a demand-side deterioration included in this outlook?